|
Market Cap | 43.58B | EPS (ttm) | 2.29 |
P/E | 15.66 | EPS this Y | 1.65% |
Forward P/E | 11.24 | EPS next Y | 5.39% |
PEG | 3.85 | EPS past 5Y | - |
P/S | 1.64 | EPS next 5Y | 4.07% |
P/B | 0.88 | EPS Q/Q | -3.32% |
Dividend | 4.46% | Sales Q/Q | -1.20% |
Insider Own | 0.38% | Inst Own | 79.34% |
Insider Trans | -3.86% | Inst Trans | 2.86% |
Short Float | 1.94% | Earnings | May 01/b |
Analyst Recom | 2.09 | Target Price | 39.61 |
Avg Volume | 8.17M | 52W Range | 30.68 - 41.33 |
|
|
|
The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
La Lande Rashida | Chief Lgl & Corp Affairs Ofcr | May 06 '24 | Sale | 35.95 | 10,140 | 364,552 | 158,266 | May 08 04:53 PM | Onell Cory | Chief Omnich Sales & AEM Ofcr | Mar 12 '24 | Sale | 34.62 | 14,289 | 494,717 | 145,680 | Mar 14 04:29 PM | La Lande Rashida | Chief Lgl & Corp Affairs Ofcr | Mar 04 '24 | Sale | 35.02 | 16,209 | 567,573 | 166,954 | Mar 05 05:06 PM | Patricio Miguel | Director | Jan 02 '24 | Sale | 38.02 | 131,500 | 4,999,025 | 992,049 | Jan 04 04:23 PM | La Lande Rashida | EVP, Global GC & CSCAO | Nov 24 '23 | Sale | 35.00 | 13,238 | 463,338 | 153,494 | Nov 28 04:44 PM |
|
|
|
|
Market Cap | 1.68B | EPS (ttm) | 1.51 |
P/E | 49.63 | EPS this Y | 32.28% |
Forward P/E | 38.59 | EPS next Y | 9.66% |
PEG | 8.27 | EPS past 5Y | 3.45% |
P/S | 8.38 | EPS next 5Y | 6.00% |
P/B | 5.62 | EPS Q/Q | 62.24% |
Dividend | 0.85% | Sales Q/Q | 13.60% |
Insider Own | 10.32% | Inst Own | 91.09% |
Insider Trans | -13.41% | Inst Trans | -1.43% |
Short Float | 4.25% | Earnings | May 02/a |
Analyst Recom | 1.50 | Target Price | 78.57 |
Avg Volume | 138.70K | 52W Range | 44.27 - 76.24 |
|
|
|
LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company focuses on the design, marketing, sales, service, and technical support of medical devices and implants for the treatment of peripheral vascular disease. Its products include balloon catheters, carotid shunts, biologic patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy. The company was founded by George D. LeMaitre on November 28, 1983 and is headquartered in Burlington, MA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
LeMaitre George W | Chairman and CEO | May 08 '24 | Sale | 75.30 | 8,000 | 602,427 | 2,079,128 | May 08 04:51 PM | LeMaitre George W | Chairman and CEO | May 07 '24 | Sale | 75.51 | 46,300 | 3,496,061 | 2,087,128 | May 08 04:51 PM | LeMaitre George W | Chairman and CEO | May 06 '24 | Sale | 75.70 | 68,906 | 5,216,013 | 2,133,428 | May 08 04:51 PM | Roberts David B | President and Director | May 06 '24 | Sale | 75.62 | 5,025 | 379,990 | 14,114 | May 08 04:35 PM | LeMaitre George W | Chairman and CEO | Mar 22 '24 | Option Exercise | 47.93 | 14,808 | 709,693 | 2,202,334 | Mar 26 05:43 PM |
|
|
|
|
Market Cap | 649.94M | EPS (ttm) | -1.15 |
P/E | - | EPS this Y | 29.41% |
Forward P/E | - | EPS next Y | -26.30% |
PEG | - | EPS past 5Y | -28.57% |
P/S | 2.59 | EPS next 5Y | - |
P/B | 1.61 | EPS Q/Q | 91.60% |
Dividend | - | Sales Q/Q | 73.59% |
Insider Own | 6.69% | Inst Own | 82.87% |
Insider Trans | -15.82% | Inst Trans | -2.02% |
Short Float | 5.66% | Earnings | May 02/a |
Analyst Recom | 1.11 | Target Price | 34.33 |
Avg Volume | 250.51K | 52W Range | 9.26 - 26.70 |
|
|
|
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
BRADBURY DANIEL | Director | May 06 '24 | Sale | 24.64 | 23,323 | 574,679 | 9,981 | May 08 04:51 PM | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | May 06 '24 | Sale | 24.72 | 3,968 | 98,089 | 9,297 | May 08 04:47 PM | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | May 06 '24 | Sale | 24.72 | 2,368 | 58,537 | 62,629 | May 08 04:47 PM | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Apr 23 '24 | Sale | 20.11 | 705 | 14,177 | 9,683 | Apr 25 04:54 PM | MAETZOLD DEREK J | Pres. & Chief Exec. Officer | Apr 23 '24 | Sale | 20.11 | 421 | 8,466 | 64,997 | Apr 25 04:54 PM |
|
|
| |
|
Market Cap | 4.36B | EPS (ttm) | -2.16 |
P/E | - | EPS this Y | -32.59% |
Forward P/E | - | EPS next Y | -16.01% |
PEG | - | EPS past 5Y | -72.54% |
P/S | - | EPS next 5Y | - |
P/B | 6.18 | EPS Q/Q | -26.40% |
Dividend | - | Sales Q/Q | - |
Insider Own | 48.84% | Inst Own | 60.76% |
Insider Trans | -4.41% | Inst Trans | -1.03% |
Short Float | 20.76% | Earnings | Feb 27/b |
Analyst Recom | 1.10 | Target Price | 101.11 |
Avg Volume | 493.05K | 52W Range | 37.13 - 89.39 |
|
|
Today 10:21AM
|
Why Earnings Season Could Be Great for Nuvalent (NUVL)
(Zacks) |
May-01-24 05:05PM
|
Nuvalent Insider Sold Shares Worth $2,666,555, According to a Recent SEC Filing
(MT Newswires) |
Apr-08-24 04:30PM
|
Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024
(PR Newswire) |
Apr-05-24 07:00PM
|
Chief Legal Officer Deborah Miller Sells 3,000 Shares of Nuvalent Inc (NUVL)
(GuruFocus.com) |
06:30PM
|
ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors
(Barrons.com) |
Mar-29-24 07:01PM
|
Chief Legal Officer Deborah Miller Sells 22,000 Shares of Nuvalent Inc (NUVL)
(GuruFocus.com) |
Mar-25-24 07:01PM
|
Chief Development Officer Darlene Noci Sells 20,000 Shares of Nuvalent Inc (NUVL)
(GuruFocus.com) |
Mar-19-24 07:01PM
|
Director Emily Conley Sells 13,333 Shares of Nuvalent Inc (NUVL)
(GuruFocus.com) |
Mar-05-24 04:52PM
|
Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024
(PR Newswire) |
Feb-29-24 04:32AM
|
Nuvalent Inc (NUVL) Reports Full Year and Q4 2023 Financial Results with Strong Cash Position ...
(GuruFocus.com) |
|
Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew D. Shair in January 2017 and is headquartered in Cambridge, MA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Shair Matthew | Director | May 06 '24 | Sale | 69.48 | 37,500 | 2,605,525 | 1,462,198 | May 08 04:51 PM | Miller Deborah Ann | Chief Legal Officer | May 02 '24 | Option Exercise | 6.89 | 3,000 | 20,670 | 36,300 | May 03 04:47 PM | Miller Deborah Ann | Chief Legal Officer | May 02 '24 | Sale | 72.07 | 3,000 | 216,203 | 33,300 | May 03 04:47 PM | Shair Matthew | Director | Apr 29 '24 | Sale | 67.51 | 37,500 | 2,531,537 | 1,499,698 | May 01 04:41 PM | Shair Matthew | Director | Apr 29 '24 | Sale | 67.51 | 2,000 | 135,018 | 236,522 | May 01 04:41 PM |
|
|
|
|
Market Cap | 66.60B | EPS (ttm) | 5.40 |
P/E | 43.17 | EPS this Y | 26.14% |
Forward P/E | 31.45 | EPS next Y | 12.83% |
PEG | 2.75 | EPS past 5Y | -0.37% |
P/S | 4.30 | EPS next 5Y | 15.72% |
P/B | 8.12 | EPS Q/Q | 75.39% |
Dividend | 0.97% | Sales Q/Q | 5.05% |
Insider Own | 11.07% | Inst Own | 78.70% |
Insider Trans | -0.09% | Inst Trans | 1.12% |
Short Float | 0.82% | Earnings | Apr 30/b |
Analyst Recom | 2.46 | Target Price | 243.63 |
Avg Volume | 1.26M | 52W Range | 156.72 - 233.30 |
|
|
|
Ecolab, Inc. engages in providing products and services in the field of water, hygiene, and energy. It operates through the following segments: Global Industrial, Global Institutional and Specialty, Global Energy and Life Science, and Other. The Global Industrial segment relates to water, food and beverage, paper, and downstream operating segments. The Global Institutional and Specialty segment refers to the institutional, specialty, and healthcare operating segments. The Global Healthcare and Life Sciences segment includes the healthcare and life sciences operations. The Other segment is involved in providing services to detect, eliminate and prevent pests. The company was founded by Merritt J. Osborn in 1923 and is headquartered in St. Paul, MN. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
HIGGINS ARTHUR J | Director | May 06 '24 | Option Exercise | 113.94 | 4,500 | 512,712 | 30,048 | May 08 04:49 PM | HIGGINS ARTHUR J | Director | May 06 '24 | Sale | 227.52 | 4,500 | 1,023,854 | 25,548 | May 08 04:49 PM | MacLennan David | Director | May 03 '24 | Buy | 227.37 | 650 | 147,788 | 17,111 | May 07 04:34 PM | Busch Angela M | EVP - CORP STRAT & BUS DEV | Mar 15 '24 | Option Exercise | 107.69 | 6,118 | 658,817 | 21,272 | Mar 19 04:39 PM | Vautrinot Suzanne M | Director | Mar 15 '24 | Option Exercise | 104.85 | 2,900 | 304,065 | 9,895 | Mar 19 04:42 PM |
|
|
| |
|
Market Cap | 4.36B | EPS (ttm) | 1.31 |
P/E | 42.73 | EPS this Y | 54.03% |
Forward P/E | 33.00 | EPS next Y | 51.31% |
PEG | 2.14 | EPS past 5Y | -5.30% |
P/S | 6.56 | EPS next 5Y | 20.00% |
P/B | 4.69 | EPS Q/Q | 1494.83% |
Dividend | - | Sales Q/Q | 0.76% |
Insider Own | 1.03% | Inst Own | 99.37% |
Insider Trans | -11.45% | Inst Trans | -0.98% |
Short Float | 3.26% | Earnings | May 01/a |
Analyst Recom | 2.20 | Target Price | 51.66 |
Avg Volume | 519.69K | 52W Range | 27.46 - 56.98 |
|
|
|
FormFactor, Inc. engages in the provision of test and measurement solutions. It operates through the following business segments: Probe Cards and Systems. The Probe Cards segment consists of technologies and product architectures, including micro-electromechanical systems technologies. The Systems segment consists of analytical probe solutions for on-wafer probing, board tests, and package tests. The company was founded by Igor Khandros on April 15, 1993 and is headquartered in Livermore, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Rhodes Sheri | Director | May 07 '24 | Sale | 56.02 | 13,319 | 746,144 | 7,634 | May 08 04:48 PM | STEVEN-WAISS KELLEY | Director | May 06 '24 | Sale | 54.24 | 4,800 | 260,335 | 32,593 | May 08 04:29 PM | SLESSOR MIKE | CEO | May 01 '24 | Sale | 43.75 | 4,000 | 174,982 | 491,781 | May 02 04:28 PM | SLESSOR MIKE | CEO | Apr 01 '24 | Sale | 45.94 | 4,000 | 183,755 | 495,781 | Apr 02 04:45 PM | Shahar Shai | CFO, SVP Global Finance | Mar 04 '24 | Sale | 44.51 | 10,000 | 445,122 | 27,591 | Mar 05 08:42 PM |
|
|
|
|
Market Cap | 2.53B | EPS (ttm) | 0.78 |
P/E | 20.87 | EPS this Y | 77.59% |
Forward P/E | 10.41 | EPS next Y | 19.18% |
PEG | 1.39 | EPS past 5Y | 13.28% |
P/S | 1.68 | EPS next 5Y | 15.00% |
P/B | 2.71 | EPS Q/Q | 59.54% |
Dividend | 6.07% | Sales Q/Q | 9.60% |
Insider Own | 17.48% | Inst Own | 81.86% |
Insider Trans | -14.89% | Inst Trans | - |
Short Float | 4.25% | Earnings | May 02/b |
Analyst Recom | 1.00 | Target Price | 17.67 |
Avg Volume | 721.57K | 52W Range | 10.76 - 15.91 |
|
|
|
Laureate Education, Inc. engages in the provision of higher educational services to undergraduate and graduate degree programs. It operates through the Mexico segment and Peru segment. The Mexico and Peru segments include the operation and management of universities. The company was founded by Douglas L. Becker in 1989 and is headquartered in Miami, FL. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Snow Ian Kendell | Director | May 06 '24 | Sale | 14.64 | 2,114,928 | 30,962,546 | 0 | May 08 04:45 PM | del Corro Pedro | Director | Mar 05 '24 | Sale | 12.62 | 24,343 | 307,209 | 0 | Mar 18 06:37 PM | del Corro Pedro | Director | Mar 05 '24 | Sale | 12.62 | 1,086 | 13,705 | 46,729 | Mar 18 06:37 PM | Wengen Alberta, LP | 10% Owner | Dec 04 '23 | Sale | 13.25 | 200 | 2,650 | 18,405,416 | Dec 05 07:35 PM | Snow Ian Kendell | Director | Dec 04 '23 | Sale | 13.25 | 179 | 2,372 | 2,688,386 | Jan 05 07:42 PM |
|
|
| |
|
Market Cap | 39.60B | EPS (ttm) | 0.78 |
P/E | 72.47 | EPS this Y | 5.21% |
Forward P/E | 16.44 | EPS next Y | 22.10% |
PEG | 5.34 | EPS past 5Y | - |
P/S | 2.35 | EPS next 5Y | 13.57% |
P/B | 1.60 | EPS Q/Q | -28.24% |
Dividend | 1.20% | Sales Q/Q | -8.03% |
Insider Own | 0.17% | Inst Own | 82.98% |
Insider Trans | -0.51% | Inst Trans | -0.09% |
Short Float | 1.38% | Earnings | May 01/a |
Analyst Recom | 1.58 | Target Price | 63.14 |
Avg Volume | 3.30M | 52W Range | 43.22 - 59.04 |
|
|
|
Corteva, Inc. engages in the provision of seed and crop protection solutions, which engages in the agriculture industry and food supply. It operates through the Seed and Crop Protection segments. The Seed segment involves the development and supply of advanced germplasm and traits that produce yield for farms. The Crop Protection segment includes the global agricultural input industry with products for weeds, insects, other pests, and diseases protection, through nitrogen management and seed-applied technologies. The company was founded in 1802 and is headquartered in Indianapolis, IN. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
TITUS BRIAN | See Remarks | May 06 '24 | Option Exercise | 41.94 | 2,134 | 89,500 | 25,625 | May 08 04:44 PM | TITUS BRIAN | See Remarks | May 06 '24 | Sale | 56.65 | 12,134 | 687,338 | 13,495 | May 08 04:44 PM | Eathington Samuel R | See Remarks | Nov 28 '23 | Buy | 46.07 | 1,094 | 50,401 | 41,066 | Nov 29 04:36 PM | GLENN TIMOTHY P | EVP, Seed Business Unit | Nov 14 '23 | Buy | 45.99 | 4,000 | 183,944 | 163,121 | Nov 15 04:54 PM | King Robert D. | EVP, Crop Protection Business | Nov 14 '23 | Buy | 46.77 | 640 | 29,933 | 59,701 | Nov 15 04:55 PM |
|
|
|
|
Market Cap | 1.37B | EPS (ttm) | 4.80 |
P/E | 8.14 | EPS this Y | 5.28% |
Forward P/E | 7.76 | EPS next Y | 14.35% |
PEG | 0.54 | EPS past 5Y | - |
P/S | 0.49 | EPS next 5Y | 15.00% |
P/B | 2.47 | EPS Q/Q | 39.04% |
Dividend | 0.72% | Sales Q/Q | 0.10% |
Insider Own | 4.05% | Inst Own | 94.94% |
Insider Trans | -20.88% | Inst Trans | -1.72% |
Short Float | 13.40% | Earnings | Mar 19/b |
Analyst Recom | 1.50 | Target Price | 44.67 |
Avg Volume | 437.98K | 52W Range | 16.85 - 41.94 |
|
|
|
Caleres, Inc. engages in the provision of athletic, casual, and dress footwear products. It operates through the Famous Footwear and Brand Portfolio segments. The Famous Footwear segment provides branded footwear for the entire family. The Brand Portfolio segment sources, manufactures, and markets branded, licensed, and private-labeled footwear primarily to online retailers, national chains, department stores, mass merchandisers, and independent retailers. The company was founded by George Warren Brown in 1878 and is headquartered in St. Louis, MO. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Schmidt John W | President & CEO, Caleres | May 06 '24 | Sale | 37.63 | 25,332 | 953,168 | 348,771 | May 08 04:43 PM | SULLIVAN DIANE M | Executive Chair | Apr 24 '24 | Sale | 37.09 | 6,856 | 254,314 | 254,668 | Apr 26 02:59 PM | SULLIVAN DIANE M | Executive Chair | Apr 23 '24 | Sale | 37.42 | 24,499 | 916,707 | 261,524 | Apr 24 05:12 PM | SULLIVAN DIANE M | Executive Chair | Apr 22 '24 | Sale | 35.99 | 12,126 | 436,411 | 286,023 | Apr 24 05:12 PM | Freidman Daniel R | Chief Sourcing Officer | Apr 08 '24 | Sale | 37.00 | 15,000 | 555,000 | 64,167 | Apr 10 04:43 PM |
|
|
|
|
Market Cap | 959.24M | EPS (ttm) | 0.52 |
P/E | 92.70 | EPS this Y | 34.01% |
Forward P/E | 59.64 | EPS next Y | 22.59% |
PEG | 6.18 | EPS past 5Y | -0.55% |
P/S | 14.83 | EPS next 5Y | 15.00% |
P/B | 5.42 | EPS Q/Q | -2.46% |
Dividend | 0.50% | Sales Q/Q | 16.22% |
Insider Own | 18.79% | Inst Own | 78.77% |
Insider Trans | -4.36% | Inst Trans | 3.69% |
Short Float | 7.31% | Earnings | Apr 03/a |
Analyst Recom | 1.00 | Target Price | 53.67 |
Avg Volume | 110.09K | 52W Range | 32.69 - 52.69 |
|
|
|
Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The firm operates through the Software and Services segment. It designs and develops pharmaceutical simulation software to promote cost-effective solutions to a number of problems in pharmaceutical research and in the education of pharmacy and medical students. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered in Lancaster, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
WEINER DANIEL L | Director | May 07 '24 | Option Exercise | 34.23 | 2,000 | 68,460 | 12,009 | May 08 04:42 PM | WEINER DANIEL L | Director | May 07 '24 | Sale | 48.31 | 3,250 | 157,008 | 8,759 | May 08 04:42 PM | LaVange Lisa | Director | May 07 '24 | Sale | 48.30 | 650 | 31,395 | 7,873 | May 08 04:39 PM | WOLTOSZ WALTER S | Director | May 01 '24 | Sale | 45.95 | 20,000 | 918,984 | 3,580,857 | May 02 04:37 PM | WOLTOSZ WALTER S | Director | Apr 01 '24 | Sale | 39.94 | 20,000 | 798,867 | 3,600,195 | Apr 02 04:32 PM |
|
|
|